TriSalus Life Sciences (TLSI) Assets Average (2021 - 2026)

TriSalus Life Sciences has reported Assets Average for 6 years, with the latest figure at $53.2 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 102.13% year-over-year to $53.2 million; the trailing twelve-month figure through Mar 2026 stood at $53.2 million (up 102.13% YoY), and the FY2025 full-year result was $29.7 million, up 22.1% from the prior year.
• Assets Average for Q1 2026 stood at $53.2 million, up from $35.9 million in the prior quarter.
• The five-year high for Assets Average was $250.9 million in Q3 2022, with the low at $16.4 million in Q2 2023.
• Historically, Assets Average has averaged $74.7 million across 5 years, with a median of $30.0 million in 2024.
• Annual changes were most pronounced in 2023 — Assets Average slumped 93.46% — and 2026, when it surged 102.13%.
• TriSalus Life Sciences' Assets Average stood at $136.7 million in 2022, then tumbled by 78.72% to $29.1 million in 2023, then dropped by 11.53% to $25.7 million in 2024, then soared by 39.55% to $35.9 million in 2025, then surged by 48.08% to $53.2 million in 2026.
• The last three Assets Average figures came in at $53.2 million (Q1 2026), $35.9 million (Q4 2025), and $38.9 million (Q3 2025), per Business Quant data.